Showing results (401-410 of 419) with videos related to

Sort By:
Pageof 42
Journal of Medicinal Chemistry|October 20, 2021
Interfering with the Tumor-Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 InhibitorsPasquale Russomanno, Giulia Assoni, Jussara Amato, et al.
Molecular Cancer|March 26, 2024
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLCGiovanna Polcaro, Luigi Liguori, Valentina Manzo, et al.
Journal of Anesthesia, Analgesia and Critical Care|April 30, 2026
A prospective multimethod investigation of cancer-related pain integrating clinical data and machine learning: results from the RUGGI StudyMarco Cascella, Cosimo Guerra, Rosario De Feo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2021
A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid TumorsXinyuan Lei, Zhanpeng Ou, Zhaohui Yang, et al.
Nature Medicine|August 25, 2025
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial resultsNiu Liu, Jiaying Wu, Enze Deng, et al.
Journal of Medicinal Chemistry|February 23, 2026
Coupling PD-L1 Inhibition and Lysosomal Degradation: Innovative Anti-PD-L1 Peptides for NSCLC ImmunotherapyFrancesco Merlino, Valentina Pagliara, Vincenzo Maria D'Amore, et al.
Immunity|December 3, 2020
The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune ResponsesMarlieke L M Jongsma, Antonius A de Waard, Matthijs Raaben, et al.
The Journal of Clinical Investigation|May 20, 2020
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapyLina Such, Fang Zhao, Derek Liu, et al.
Cancers|November 13, 2025
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal CancersMaurizio Capuozzo, Carmine Picone, Francesco Sabbatino, et al.
Cancer Cell|October 11, 2022
Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapyEvgenii N Tcyganov, Emilio Sanseviero, Douglas Marvel, et al.
Pageof 42